A multicenter study in Malaysia to determine the efficacy and safety of a generic atorvastatin

Medical Journal of Malaysia

Volumn 64, Issue 2, 2009, Pages 150-154

  Punithavathi, N ^a   Ong, Loke Meng ^a   Lena, Y L L ^a   Leekha, S ^b  

^a Penang Adventist Hospital   (Malaysia)

^b Ranbaxy ^*  (Malaysia)

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A (HMG CoA) reductase inhibitors; Atorvastatin; Coronary Heart Disease (CHD); Generic statins; Hypercholesterolemia; Storvas

Indexed keywords

ATORVASTATIN; GENERIC DRUG; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; STORVAS; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; HEPTANOIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; PATIENT COMPLIANCE; PRURITUS; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; MIDDLE AGED;

ADULT; AGED; CHOLESTEROL, LDL; DRUGS, GENERIC; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PYRROLES;

EID: 77449137953     PISSN: 03005283     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Keys A, editor. Coronary heart disease in seven countries. Circulation 1970; 41(Suppl 1): 1-211.
2. Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study. J Am Med Assoc 1995; 274: 131-6.
3. Assmann G, Cullen P, Schulte H. The Munster Heart Study (PROCAM): results of follow-up at 8 years. Eur Heart J 1998; 19(Suppl A): A2-A11.
4. Wilson PW, Anderson KM, Castelli WP. Twelve-year incidence of coronary heart disease in middle aged adults during the era of hypertensive therapy: the Framingham Offspring Study. Am J Med 1991; 90: 11-6.
5. Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentrations and coronary heart disease in population with low cholesterol concentrations. Br Med J 1991; 303: 276-82.
6. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986; 256(20): 2823-8.
7. Lim TO, Ding LM, Zaki M, Suleiman AB et al. Distribution of blood total cholesterol in a national sample of Malaysian adults. Med J Malaysia 2000; 55: 78-89.
8. Pfizer Parke-Davis. Lipitor® (atorvastatin calcium) tablets prescribing information. New York, NY; 2005 Sep.
9. Nawrocki JW, Weiss SR, Davidson MH et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 1995; 15(5): 678-82.
10. McVey D, Patel H, Eminton Z et al. An assessment of the efficacy of atorvastatin in treating patients with dyslipidaemia to target LDL-cholesterol goals: the atorvastatin matrix study. Int J Clin Pract. 1999; 53(7): 509-13.
11. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients with hypercholesterolemia. J Cardiovasc Pharmacol Ther. 2000; 5(1): 27-32.
12. Japan Cholesterol Lowering Atorvastatin study (J-CLAS) group. Efficacy of atorvastatin in primary hypercholesterolemia. Am J Cardiol 1997; 79: 1248-51.
13. Sameerah S.A.R, Sarojini S. (Eds). Malaysian Statistics on Medicine 2005. Kuala Lumpur 2007.
14. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert Panel on Detection, Evaluation and treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
15. Australian Statistics on Medicine 1999-2000.Commonwealth Department of health and ageing Australia 2003.
16. Insull W, Kafonek S, Goldner D et al. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Am J Cardiol. 2001; 87(5): 554-9.
17. Karalis DG, Ross AM, Vacari RM, et al. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease. Am J Cardiol. 2002; 89(6): 667-71.
18. Sever PS, Dahlof B, Poulter NR, Wedel H, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004; 64 Suppl 2: 43-60.
19. Kim HS, Wu Y, Lin SJ, Deerochanawong C, Current status of cholesterol goal attainment after statin therapy among patients with hypercholesterolemia in Asian countries and region: the Return on Expenditure Achieved for Lipid Therapy in Asia (REALITY-Asia) study. Curr Med Res Opin. 2008; 24(7): 1951-63.
20. Kim S-H, Sung JD, Kim H-S. 2007 Ten Center Follow-up Study. Presented at the Annual Scientific Session of the Korean Circulation Society, September 12, 2007.